Related Topics News -

     
 Title only   |   Print    Next page > 
     
派格生物醫藥創新候選產品CR059入選ADA最新突破性摘要

2026-04-07T  
《業績》派格生物醫藥全年虧損收窄至2.08億人民幣

2026-03-23T  
派格生物與騰瑞製藥達成商業化合作 目標規模逾百億人民幣

2026-03-16T  
派格生物醫藥每手改50股買賣 本月31日生效

2026-03-10T  
派格生物醫藥:新一代GLP-1首次人體試驗取得一個月臨床觀察結果

2026-03-06T  
派格生物醫藥基石投資者再次延長禁售期

2025-12-15T  
派格生物醫藥折讓一成配股 淨籌2.96億元

2025-12-14T  
派格生物醫藥擬轉換近1.02億股未上市股份為H股 佔已發行股份總數26.4%

2025-11-28T  
派格生物醫藥基石投資者禁售期延至年底

2025-11-26T  
國家藥監局批准創新藥維培那肽注射液上市

2025-11-21T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.